SABCS 2022 | The role of the Oncotype DX assay in the management of patients with breast cancer

Prashanth Ashok Kumar, MD, Upstate University Hospital, Syracuse, NY, provides an overview of the Oncotype DX assay and its impact on the management of patients with breast cancer. Oncotype DX assay aids in the identification of patients who may benefit from adjuvant chemotherapy and when chemotherapy can be safely omitted. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.